相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity
Thomas P. Ahern et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2017)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P. Saladores et al.
PHARMACOGENOMICS JOURNAL (2015)
No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients
Andrea Markkula et al.
ACTA ONCOLOGICA (2014)
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy
Jessica Mwinyi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
K. R. Crews et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen
Christos Markopoulos et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C
Joohwan Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2013)
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
Kathryn J. Ruddy et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
F. L. Opdam et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
Sara Margolin et al.
PHARMACOGENOMICS (2013)
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
Richard R. Love et al.
SPRINGERPLUS (2013)
The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
L. K. Teh et al.
AAPS JOURNAL (2012)
Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
Chonlaphat Sukasem et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
In Hae Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
I. Sestak et al.
BRITISH JOURNAL OF CANCER (2012)
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
Solai Elango Damodaran et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Yusuke Nakamura et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment
Christine M. Walko et al.
PHARMACOGENOMICS (2012)
Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
Matthew P. Goetz et al.
CLINICAL CANCER RESEARCH (2011)
Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
M. F. Barginear et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
T. E. Muerdter et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
William J. Irvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
Hyung Seok Park et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2011)
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
T. Ramon y Cajal et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
Jean E. Abraham et al.
BREAST CANCER RESEARCH (2010)
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Monique J. Bijl et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen
Masatsugu Okishiro et al.
CANCER (2009)
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
William G. Newman et al.
CLINICAL CANCER RESEARCH (2008)
Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer
L. W. M. Loo et al.
GENES CHROMOSOMES & CANCER (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
Hyeong-Seok Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
分享论文
